Study of a new drug for blood cell disorders with SF3B1 mutation
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an investigational drug called REGN17235 in people with certain low-risk blood disorders (MDS or CCUS) that have a specific genetic change (SF3B1 mutation). The goal is to see if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood disorder called low-risk myelodysplastic syndrome (MDS) or clonal cytopenia of undetermined significance (CCUS) with a specific genetic change (SF3B1 mutation).
- Your bone marrow is working well enough, and you may need red blood cell transfusions.
- Your liver and kidney function must be within acceptable limits.
- You have not had other causes of anemia (like iron deficiency or vitamin B12 deficiency) in the last 3 months.
- You have no recent or uncontrolled infections, and no other cancer that is currently being treated.
- You have not had certain treatments for MDS or CCUS recently, and you have not had a stem cell transplant in the last 100 days or have active graft-versus-host disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an early treatment for people with a condition called high-risk CCUS, where low blood counts and gene changes raise the risk of developing blood cancer. The goal is to see if intervening early can prevent or delay progression to leukemia or MDS.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This Phase 2 trial studies whether a statin medicine can help people with CCUS (a bone-marrow condition with abnormal genetic mutations) or lower-risk MDS (a blood disorder) that causes persistent low blood counts. It aims to see if statins can improve blood-related outcomes while keeping you safe from side effects.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
This early-stage trial tests a new drug called HRS-1635 in patients with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to previous treatment. The goal is to find the right dose and understand how well and safely the drug works.
Hear when a new Clonal Cytopenia of Undetermined Significance (CCUS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.